Novo Nordisk CEO on medicare coverage, new obesity pill, U.S. pricing pressure

Joining me now is Novo Nordisk CEO Mike Doustdar. Thanks so much for making time today. Thank you very much.Great. So I really appreciate the time. And so this year we've seen the explosive launch of your Wegovy pill.But we've also seen an outlook that diverges from your competitor despite the same pricing headwinds. And so what would be your message to investors who feel mixed about the trajectory of your business in 2026. We have, for a while now has been speaking at 2026 will be a different year, differe ...